ARS Pharmaceuticals, Inc.
SPRY · Nasdaq · United States
Share price · SPRY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SPRY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+10.6%
Nothing announced by SPRY that day or the session before.
- 10 Nov 2026+13.3%
Nothing announced by SPRY that day or the session before.
- 9 Nov 2026+12.9%
Nothing announced by SPRY that day or the session before.
- 9 Oct 2026-7.2%
Nothing announced by SPRY that day or the session before.
- 25 Jun 2026-23.9%
- 28 May 2026+10.6%
Nothing announced by SPRY that day or the session before.
- 13 May 2026-7.2%
- 22 Apr 2026+7.1%
Nothing announced by SPRY that day or the session before.
- 26 Mar 2026+8.4%
Nothing announced by SPRY that day or the session before.
- 12 Jan 2026-12.9%
Nothing announced by SPRY that day or the session before.
Share of unusual movement by asset
For each asset, the share of SPRY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Epinephrine(neffy) | Approved | Alpha- and beta-adrenergic receptors (agonist)Small molecule | Allergic Conditions Anaphylaxis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
June 2027 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $38M | $18M | $26M+ $113M short-term inv. | $36M-$34M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $34M | $4.7M | $8.2M+ $136M short-term inv. | $62M-$61M operating cash flow | report ↗ |
| 2026-Q1 | $23M | $4.3M | $24M+ $177M short-term inv. | $61M-$45M operating cash flow | report ↗ |
| 2025-Q3 | $33M | $2.8M | $60M+ $229M short-term inv. | $51M-$47M operating cash flow | report ↗ |
| 2025-Q2 | $16M | $4.0M | $52M+ $189M short-term inv. | $45M-$40M operating cash flow | report ↗ |
| 2025-Q1 | $8.0M | $3.0M | $40M+ $236M short-term inv. | $34M-$41M operating cash flow | report ↗ |
| 2024-Q3 | $2.1M | $4.4M | $40M+ $165M short-term inv. | $19M-$14M operating cash flow | report ↗ |
| 2024-Q2 | $0.5M | $6.9M | $37M+ $182M short-term inv. | $13M-$7.3M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $5.2M | $56M+ $168M short-term inv. | $10M-$6.7M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $3.0M | $61M+ $181M short-term inv. | $15M-$13M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $7.3M | $119M+ $133M short-term inv. | $17M-$17M operating cash flow | report ↗ |
| 2023-Q1 | <$0.1M | $6.5M | $88M+ $177M short-term inv. | $15M-$12M operating cash flow | report ↗ |
| 2022-Q3 | $0.2M | $8.4M | $203M+ $63M short-term inv. | $18M-$17M operating cash flow | report ↗ |
| 2022-Q2 | $0.5M | $12M | $219M+ $39M short-term inv. | $19M-$15M operating cash flow | report ↗ |
| 2022-Q1 | $0.7M | $17M | $234M+ $20M short-term inv. | $25M-$20M operating cash flow | report ↗ |
| 2021-Q3 | — | $16M | $301M | $23M-$19M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $84M | $13M | $41M+ $204M short-term inv. | $43M-$171M operating cash flow | report ↗ |
ARS Pharmaceuticals reported full-year 2025 total revenue of $84.28M, down 5.5% YoY, composed of $72.2M in U.S. neffy net product revenue, $9.7M in collaboration revenue, and $2.4M in supply revenue. R&D spend was $13.18M, down 32.7% YoY. Cash and equivalents were $41.32M, while total cash, cash equivalents, and short-term investments were $245.0M at year-end. The company reported a net loss of $171.3M, or $1.74 per share, and a quarterly net burn of $171.3M.
Management stated that the year-end cash position is expected to fund operations through anticipated cash-flow break-even, with similar annualized promotional investment planned for 2026. Commercial highlights included more than 22,500 prescribing healthcare providers, over 9,000 schools in the neffy inSchools program, about 10% of neffy prescription volume facilitated through getneffy.com, and a planned sales force expansion from 106 to 150 representatives beginning in the second quarter of 2026. Regulatory and clinical developments included neffy approvals in China and Australia in December 2025, a positive CHMP opinion for EUR neffy 1 mg in January 2026, an expected Canadian approval in the second quarter of 2026, and an ongoing Phase 2b trial in chronic spontaneous urticaria with interim data anticipated in the second half of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $89M | $20M | $51M+ $263M short-term inv. | —$14M operating cash flow | report ↗ |
| 2023-FY | <$0.1M | $20M | $71M+ $157M short-term inv. | $14M-$59M operating cash flow | report ↗ |
| 2022-FY | $1.3M | $18M | $211M+ $64M short-term inv. | $8.7M-$40M operating cash flow | report ↗ |
| 2021-FY | $5.5M | $62M | $254M+ $0 short-term inv. | $22M-$67M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($284K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Slebir John L · Chief Legal Officer | Award / grant (derivative) | 1,199,482 | — | — | Form 4 |
| 2026-10-01 | Casale Donn · director, President and CEO | Award / grant (derivative) | 1,036,923 | — | — | Form 4 |
| 2026-09-01 | Smith Margaret Ekins · Chief Commercial Officer | Award / grant (derivative) | 1,001,738 | — | — | Form 4 |
| 2026-07-01 | Casale Donn · President | Award / grant (derivative) | 898,456 | — | — | Form 4 |
| 2026-06-24 | Shawver Laura · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-24 | SCHNEIDER PHILLIP M · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-24 | SAUNDERS BRENT L · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-24 | Thompson Peter A. · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 201 reporting institutions held 93.3M shares ($732.9M, 93.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 10,860,977 | $87.2M |
| 2 | ORBIMED ADVISORS LLC | 8,288,510 | $66.6M |
| 3 | Rubric Capital Management LP | 8,000,000 | $64.2M |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 7,503,812 | $60.3M |
| 5 | MILLENNIUM MANAGEMENT LLC | 5,982,919 | $48.0M |
| 6 | BlackRock, Inc. | 5,012,254 | $40.2M |
| 7 | Aberdeen Group plc | 4,113,617 | $33.0M |
| 8 | SR One Capital Management, LP | 4,012,903 | $32.2M |
| 9 | STATE STREET CORP | 3,644,966 | $29.3M |
| 10 | FRANKLIN RESOURCES INC | 3,278,549 | $26.3M |
| 11 | Tyro Capital Management LLC | 2,968,599 | $23.8M |
| 12 | VANGUARD CAPITAL MANAGEMENT LLC | 2,542,504 | $20.4M |
| 13 | UBS Group AG | 2,260,325 | $18.2M |
| 14 | CITADEL ADVISORS LLC | 1,773,188 | $14.2M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 1,526,824 | $12.3M |